Oncopeptides AB (publ)
SSE:ONCO.ST
7.264 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||
| Net Income
| -249.111 | -349.35 | -1,420.917 | -1,591.279 | -739.392 | -419.3 | -247.62 | -114.482 | -53.35 | -33.11 |
| Depreciation & Amortization
| 11.04 | 17.161 | 14.994 | 14.403 | 4.54 | 0.345 | 0.234 | 0.024 | 0.007 | 0.007 |
| Deferred Income Tax
| 0 | -19.146 | 34.198 | -68.209 | 0 | -0.149 | 0 | 0.036 | 0 | 0 |
| Stock Based Compensation
| 9.49 | 19.146 | -34.198 | 68.209 | 32.493 | 12.368 | 2.519 | 10.2 | 0 | 0 |
| Change In Working Capital
| -54.629 | -109.233 | -38.082 | 142.27 | 58.699 | 40.848 | -54.562 | -0.085 | 0.526 | 1.648 |
| Accounts Receivables
| -16.02 | 53.174 | 24.657 | -7.747 | -29.962 | -0.769 | -59.153 | -12.107 | -0.959 | -0.447 |
| Inventory
| -1.334 | -1.456 | -0.319 | -0.429 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| -13.194 | -22.887 | -104.911 | 55.149 | 55.716 | 9.589 | 6.95 | 3.616 | 0 | 0 |
| Other Working Capital
| -54.629 | -139.52 | 42.491 | 95.297 | 32.945 | 23.691 | -2.359 | 8.406 | -1.062 | 1.032 |
| Other Non Cash Items
| 24.247 | 20.913 | -72.386 | 138.097 | -46.906 | 32.161 | 27.932 | 0.045 | 0.009 | 0.016 |
| Operating Cash Flow
| -279.493 | -420.509 | -1,516.391 | -1,296.509 | -690.566 | -333.727 | -271.497 | -104.262 | -52.808 | -31.439 |
| Investing Activities: | ||||||||||
| Investments In Property Plant And Equipment
| -0.116 | -2.507 | -0.339 | -17.18 | -2.628 | -0.369 | -1.472 | -1.117 | 0 | 0 |
| Acquisitions Net
| 0 | 0 | 0 | -0.184 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -0.001 | 0 | 0 | -3.131 | 0 | -0.8 | 0 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 0 | 0 | 0 | 0.184 | 0 | 0.262 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0.001 | 0 | 0 | 0.184 | -2.111 | 0.262 | 0 | 0 | 0 | 0 |
| Investing Cash Flow
| -0.116 | -2.507 | -0.339 | -20.127 | -2.628 | -0.907 | -1.472 | -1.117 | 0 | 0 |
| Financing Activities: | ||||||||||
| Debt Repayment
| -116.024 | -15.542 | -15.405 | -14.26 | -3.956 | 0 | 0 | -143.302 | 0 | 0 |
| Common Stock Issued
| 0 | 435.611 | 1,116.488 | 1,422.952 | 1,316.836 | 324.283 | 636.761 | 0 | 43.136 | 35.589 |
| Common Stock Repurchased
| -0.024 | -27.667 | -67.053 | -85.231 | -76.595 | -19.39 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 108.637 | 43.209 | 82.458 | 85.231 | 76.595 | -19.39 | 636.761 | 143.302 | 43.136 | 35.589 |
| Financing Cash Flow
| 108.613 | 392.402 | 1,034.03 | 1,323.461 | 1,236.285 | 304.893 | 636.761 | 143.302 | 43.136 | 35.589 |
| Other Information: | ||||||||||
| Effect Of Forex Changes On Cash
| 1.613 | 12.942 | 4.633 | -92.756 | 7.478 | 1.308 | 0.008 | 0.035 | 0 | 0 |
| Net Change In Cash
| -171.108 | -17.672 | -478.068 | -85.931 | 550.569 | -28.433 | 363.799 | 37.958 | -9.673 | 4.151 |
| Cash At End Of Period
| 173.407 | 344.515 | 362.187 | 840.255 | 926.186 | 375.617 | 404.05 | 40.251 | 2.293 | 11.966 |